Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

NCT03681548

Ovarian Cancer Recurrent

COMPLETED PHASE1

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

NCT02237690

Ovarian Cancer

COMPLETED PHASE1

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

NCT01815294

Neoplasms Neoplasms, Ovarian Neoplasms, Breast +1 more

COMPLETED PHASE1

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

NCT00720096

Ovarian Cancer

TERMINATED NA

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

NCT00189410

Cancer of the Ovary Treated as 2nd Line Therapy Muellerian Mixed Tumours Tumours of the Uterus +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study has sequential two stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of stage 1. Power analysis will be performed for the primary pharmacokinetic parameters of free Doxorubicin and liposome encapsulated Doxorubicin, for all completed patients before bioequivalence evaluation. If observed power will be \>= 80% then two one-sided 90% CI will be calculated for bioequivalence assessment at stage I.

If observed power will be \< 80% then bioequivalence will be evaluated at stage I. If bioequivalence met then study will be stopped and if bioequivalence not met, then required additional patients will be enrolled in stage II.

Each patient will be randomized to one of the two treatment sequences ( RT or TR ) according to a randomization scheme prepared prior to the start of the trial. Serial blood samples for determination of free doxorubicin and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle .

Bioequivalence Criteria : The 94.12% confidence intervals for the ratio of geometric least squares means of ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf should be within 80.00 to125.00% to conclude the test product is bioequivalent to the reference product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Epithelial Cancer Recurrent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Product - T

doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )

Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks.

Group Type EXPERIMENTAL

Doxorubicin Hydrochloride Liposome Injection

Intervention Type DRUG

50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.

Reference Product - R

doxorubicin hydrochloride liposome ( Sun Pharma )

Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks.

Group Type ACTIVE_COMPARATOR

Doxorubicin Hydrochloride Liposome Injection

Intervention Type DRUG

50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxorubicin Hydrochloride Liposome Injection

50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female of Indian Nationality , between 18-60n years of age
* Able to understand investigational nature of this study and give written informed consent prior to the participation in the trial.
* Patients with ovarian cancer requiring Doxorubicin and whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with reference listed drug
* ECOG performance status ≤ 2
* Cardiac function ( LVEF) ≥ 50%
* patient with life expectancy of at least 3 months
* Adequate hematopoietic, renal and liver function

Exclusion Criteria

* Prior doxorubicin exposure that would result in a total lifetime exposure of 550mg/m2 or more after four cycles of treatment .
* Pregnant or breast-feeding female
* active opportunistic infection with mycobacteria , cytomegalovirus , toxoplasma
* Impaired cardiac function including any of the following conditions within past 6 months :

1. Unstable angina
2. QTc prolongation or other significant ECG abnormalities
3. Coronary artery bypass graft surgery
* History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCl or the components of Doxorubicin Hydrochloride liposome injection.
* known brain metastasis
* HIV positive antibody or syphilis
* Patients with significantly impaired hepatic function
* Clinically significant liver and kidney disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No